# FUNCTIONAL INSUFFICIENCY OF ERYTHROCYTE THROMBOPLASTIN FACTOR\*

#### I. Ya. Ashkinazi

UDC 616.151.514-092

The study of the thromboplastin activity of whole erythrocytes of healthy and sick persons revealed disturbances of the procoagulant properties of the erythrocytes, manifested as a decrease in the thromboplastin activity of the whole cell, despite an adequate content of the procoagulant factor in it. To describe these disturbances, which are similar to changes in the procoagulant properties of platelets in one form of thrombopathy, the term "functional insufficiency of erythrocyte thromboplastin factor" shortened to "erythrocytic thrombopathy" is suggested.

KEY WORDS: erythrocyte; thromboplastin factor; disturbance of mobilization.

The writer suggested previously that the process of mobilization of erythrocyte thromboplastin factor (ETF) is coupled with changes in the dynamic properties of the cell membrane [1].

In this investigation the degree of incorporation of ETF into the blood clotting process was compared in different states of the body, a problem not previously specially investigated. It was hoped that such an analysis would assist the understanding of the physiological mechanisms controlling ETF mobilization and would also answer the question whether, under natural conditions, changes in the procoagulant properties of erythrocytes which were previously observed in vitro after certain procedures directed against the cell membrane [1, 2] are also possible under natural conditions.

These comparative studies are also interesting from the clinical standpoint. Only a few studies, yielding conflicting results, have been devoted to the coagulant activity of erythrocytes, the major constituent of the blood cells [6, 7]. In diffuse diseases of the kidneys the procoagulant activity of whole erythrocytes, unlike that of the platelets, has not been studied at all, although it is known that in chronic renal failure the activity of platelet factor 3 is reduced and that whole erythrocytes can partly compensate for its deficiency.


### EXPERIMENTAL METHOD

Since the thromboplastin activity exhibited by the whole cell is only a fraction of the activity contained in it, in order to assess the degree of mobilization of ETF not only the absolute thromboplastin activity of the erythrocytes (in seconds) was taken into consideration, but also the relative ETF – as a ratio of optimal (potential) activity of the cell; this was taken to be the activity of hemolyzed erythrocytes (the osmolysate), taken in the same dilution as the whole erythrocytes, namely 1/50 (the concentration of the original suspension of washed erythrocytes was  $4 \cdot 10^6/\text{mm}^3$ ). The relative index of erythrocyte activity (IEA) was determined as the ratio between the absolute value of the index (in seconds) in the substrate plasma after addition of erythrocytes to it and the analogous index (in seconds) in plasma containing hemolyzed erythrocytes. Platelet-deficient plasma from healthy donors of blood group AB (IV), kept at 25-30°C in silicone-treated flasks, was used as the substrate plasma. The thawed plasma, activated by diatomite, was used once only. Thromboplastin activity was estimated from the recalcification time, prothrombin consumption, and thrombin generation [2].

This material is protected by copyright registered in the name of Plenum Publishing Corporation, 227 West 17th Street, New York, N.Y. 10011. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission of the publisher. A copy of this article is available from the publisher for \$7.50.

<sup>\*</sup>Paper read at the Fourth All-Union Conference on Problems in Blood Clotting and Fibrinolysis, Saratov, 1975.

Laboratory of Experimental and Clinical Hematology, I. P. Pavlov Institute of Physiology, Academy of Sciences of the USSR, Leningrad. (Presented by Academician V. N. Chernigovskii.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 83, No. 6, pp. 664-666, June, 1977. Original article submitted November 4, 1976.






Fig. 1 Fig. 2

Fig. 1. Effect of whole erythrocytes from healthy persons and patients on thrombin generation in platelet-deficient substrate plasma: 1) before addition; 2, 3, 4) after addition of erythrocytes from healthy persons, patients with atherosclerosis, and patients with kidney diseases, respectively. Abscissa, duration of incubation of clotting mixture (in min); ordinate, thrombin activity (in sec).

Fig. 2. Effect of disintegrated erythrocytes of healthy persons and patients on thrombin generation in platelet-deficient substrate plasma. Hemolyzed erthrocytes from the following sources were added to the substrate plasma: 1) healthy persons; 2) patients with atherosclerosis; 3) patients with kidney diseases. Remainder of legend as in Fig. 1.

TABLE 1. Index of Erythrocyte Activity for Healthy Subjects and Patients (M ± m)

Subjects tested (m)	Recalcification time, sec			Maximal thrombin activity, sec			Prothrombin consumption time, sec		
	plasma with erythro- cytes	plasma with hemolysate	IEA	plasma with erythro- cytes	plasma with hemolysate	IEA	plasma with erythro- cytes	plasma with hemolysate	IEA
Healthy (22)  Patients with atherosclerosis (33)	143.5=3.52	98.3±2.56	1,48±0.04 1,49±0.03	31.6±0.63 32.3±0.70	20,2±0,52 20,2±0,50	1.58±0.05	53,5±2.76 51.0±1.86	103,9±4,34	0.52±0.02
Patients with kidney diseases (29)	148.5=2.3	99.3±3.3 92.4±1.3	1,49±0.03	35.9±0.57*	19.8±0.37	1,82=0.04*	48.0=1.72	117,3±7,0	0,44±0,03*

<sup>\*</sup> P < 0.05 compared with healthy subjects.

The 84 persons investigated were divided into groups: 1) 22 healthy persons aged 19-46 years (mean age  $33.7 \pm 1.98$  years); 2) 33 patients with atherosclerosis aged 46-78 years (mean age  $62.5 \pm 1.4$  years); 3) 29 patients with diseases of the kidneys aged 18-59 years (mean age  $36.9 \pm 2.4$  years), most of whom (22) had chronic diffuse glomerulonephritis, 12 had a disturbance of the nitrogen-excreting function of the kidneys, and 16 had impairment of filtration.

# EXPERIMENTAL RESULTS

Under the influence of intact healthy human erythrocytes a characteristic increase in the thromboplastin activity of substrate plasma was observed: The thrombin generation time was shortened and its maximal activity increased, and the prothrombin consumption was increased. Under the influence of erythrocytes from patients with atherosclerosis the same changes were observed. The thromboplastin activity of the whole

erythrocytes of patients with renal pathology was distinctly less than in healthy subjects or patients with atherosclerosis (Fig. 1). Meanwhile, the thromboplastin activity of the hemolysate, reflecting the potential procoagulant ability of the cell, was not reduced in patients with kidney diseases (Fig. 2). The above findings were reflected in a regular increase in IEA (compared with the control group) for the recalcification time and maximal thrombin activity and, correspondingly, by a decrease in IEA for the prothrombin consumption time (Table 1). The results thus did not confirm data in the literature showing an increase [6] or decrease [7] in the thromboplastin activity of the erythrocytes in atherosclerosis.

Changes in erythrocyte activity in patients with kidney diseases were the most interesting: a decrease in the thromboplastin activity of the whole cell despite the adequate content of thromboplastic factor (normal osmolysate activity). Under these circumstances no correlation was observed between disturbance of the ETF activity of the whole cell and indices characterizing the state of kidney function (the filtration level, serum urea concentration, diastolic blood pressure), evidence of the appearance of changes in the erythrocytes at a relatively early stage of the disease. Meanwhile the procoagulant properties of the platelets (including a decrease in the activity of factor 3) are disturbed as a rule only in the presence of marked renal insufficiency [4, 9, 10, 12].

The fact that the erythrocytes contained sufficient thromboplastin factor but, at the same time, the procoagulant activity of the whole cell was reduced, is evidence of a disturbance of the mobilization of ETF in the course of blood clotting. No definite similarity could be noted between the changes in ETF discussed and changes in the procoagulant properties of erythrocytes treated with trypsin [1]. This suggests a probable link between changes in ETF in kidney diseases and disturbance of the surface properties (and/or dynamic properties) of the erythrocyte membrane.

The close similarity between the disturbances found and changes in the procoagulant properties of the platelets in one form of thrombopathy, also characterized by low thromboplastin activity of the whole platelets despite their normal content of factor 3, also deserves attention [3, 5, 13]. In this case the leading role of disturbances of the dynamic properties of the cell structures is emphasized by the term "functional thrombopathy" [8, 11].

On the basis of the above account it was concluded that the disturbances of the procoagulant properties of the erythrocytes could be described by the term "functional insufficiency of erythrocyte thromboplastin factor" or, in an abbreviated form, "erythrocytic thrombopathy."

The decrease in the thromboplastin activity of the erythrocytes observed both experimentally and clinically, without the loss by the cell of its intrinsic procoagulant, a lipoprotein present as a component of the plasma membrane, explains the importance of the search for pharmacological agents by means of which functional insufficiency of ETF could be deliberately induced should thrombosis threaten.

## LITERATURE CITED

- 1. I. Ya. Ashkinazi, Byull. Éksp. Biol. Med., No. 7, 28 (1972).
- 2. I. Ya. Ashkinazi, Byull. Éksp. Biol. Med., No. 2, 20 (1974).
- 3. Z. S. Barkagan, Probl. Gematol., No. 5, 3 (1974).
- 4. G. A. Belitskaya, Vrach. Delo, No. 3, 67 (1974).
- 5. Ch. S. Guseinov, The Physiology and Pathology of the Platelets [in Russian], Moscow (1971).
- 6. A. F. Mel'nikov, Kardiologiya, No. 11, 53 (1974).
- 7. K. G. Potekhin, Yu. P. Nikitin, and V. I. Fedenkov, in: Oxidoreduction, Atherogenesis, and Ischemic Heart Disease [in Russian], Novokuznetsk (1975), pp. 119-125.
- 8. Bowie and Owen (1968), cited by O. W. Ulutin, Ann. N.Y. Acad. Sci., 201, 174 (1972).
- 9. P. A. Castaldi, M. C. Rozenberg, and J. H. Stewart, Lancet, 2, 66 (1966).
- 10. H. I. Horowitz and M. F. Papayoanou, Thrombos. Diathes. Haemorrh. (Stuttgart), 19, 18 (1968).
- 11. J. W. Linman, Principles of Hematology, Macmillan, New York (1966).
- 12. J. G. San Miguel and R. Castillio, Acta Haematol. (Basel), 40, 114 (1968).
- 13. O. W. Ulutin, Ann. N. Y. Acad. Sci., 201, 174 (1972).